Evotec AG has reached a milestone in its research alliance with Boehringer Ingelheim, triggering a payment of €4 million to Evotec. The milestone was for the transition of an oncology molecule into preclinical development.   Dr. Mario Polywka, chief operating officer of Evotec, said, “This is the 20th milestone achieved as part of our alliance with Boehringer Ingelheim and represents a second oncology compound transitioning into preclinical development. I would like to congratulate the tea...